Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PPP5C | P53041 | 2/20 | 0.32 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.32 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27128389 | 1.00 | ATM (0.37) | ATMACEAGTR2RENALDH1A1 | |
| Alcohol SCHEMBL28298325 | 0.93 | ACE (0.36) | ATMACEAGTR2REN | |
| SCHEMBL14849286 | 0.86 | ATM (0.48) | ATMACEAGTR2RENALDH1A1 | |
| SCHEMBL31597599 | 0.81 | TSHR (0.46) | ATMACEAGTR2ALDH1A1 | |
| SCHEMBL20334385 | 0.80 | ATM (0.33) | ATMACEAGTR2 | |
| SCHEMBL799809 | 0.78 | CCR2 (0.38) | ATMACERENALDH1A1CYP1A2 | |
| SCHEMBL10125636 | 0.78 | CCR2 (0.38) | ATMACERENALDH1A1CYP1A2 | |
| SCHEMBL25728480 | 0.78 | CCR2 (0.38) | ATMACERENALDH1A1CYP1A2 | |
| SCHEMBL7533067 | 0.77 | HSD17B10 (0.48) | — | |
| SCHEMBL6625172 | 0.77 | HSD17B10 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023145804-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | ATM 1037/4885ACE 3683/4885AGTR2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.